Arjun Agarwal Sells 10,290 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) SVP Arjun Agarwal sold 10,290 shares of the company’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $59.07, for a total value of $607,830.30. Following the completion of the sale, the senior vice president directly owned 16,406 shares of the company’s stock, valued at approximately $969,102.42. This represents a 38.55% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Arjun Agarwal also recently made the following trade(s):

• On Monday, March 16th, Arjun Agarwal sold 395 shares of Oruka Therapeutics stock. The shares were sold at an average price of $41.30, for a total value of $16,313.50.

Oruka Therapeutics Stock Performance

NASDAQ:ORKA opened at $57.50 on Wednesday. The firm has a market cap of $3.47 billion, a PE ratio of -29.64 and a beta of -0.20. Oruka Therapeutics, Inc. has a fifty-two week low of $10.16 and a fifty-two week high of $91.00. The business has a 50 day moving average price of $56.16 and a 200-day moving average price of $39.85.

Oruka Therapeutics (NASDAQ:ORKA) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.48) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.04. Research analysts predict that Oruka Therapeutics, Inc. will post -2.1 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. Barclays increased their price objective on Oruka Therapeutics from $78.00 to $160.00 and gave the company an “overweight” rating in a research note on Monday, April 27th. Stifel Nicolaus increased their price objective on Oruka Therapeutics from $47.00 to $72.00 and gave the company a “buy” rating in a research note on Friday, March 13th. BTIG Research reissued a “buy” rating and set a $151.00 price objective on shares of Oruka Therapeutics in a research note on Thursday, May 14th. Leerink Partners set a $120.00 price objective on Oruka Therapeutics in a research note on Thursday, April 30th. Finally, Wedbush set a $165.00 price objective on Oruka Therapeutics in a research note on Monday, April 27th. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Oruka Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $120.80.

Hedge Funds Weigh In On Oruka Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Fairmount Funds Management LLC raised its holdings in shares of Oruka Therapeutics by 9.9% during the third quarter. Fairmount Funds Management LLC now owns 3,705,262 shares of the company’s stock valued at $71,252,000 after acquiring an additional 333,340 shares in the last quarter. Secure Asset Management LLC bought a new position in Oruka Therapeutics in the fourth quarter worth $2,475,000. Avoro Capital Advisors LLC bought a new position in Oruka Therapeutics in the third quarter worth $25,640,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new position in Oruka Therapeutics in the third quarter worth $296,000. Finally, Commodore Capital LP raised its holdings in Oruka Therapeutics by 23.5% in the third quarter. Commodore Capital LP now owns 1,753,054 shares of the company’s stock worth $33,711,000 after purchasing an additional 333,340 shares in the last quarter. Institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.